Literature review: Imaging in prostate cancer

Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: Cancer J Clin, 71, 209 Yadav, 2018, Intratumor heterogeneity in prostate cancer, Urol Oncol, 36, 349, 10.1016/j.urolonc.2018.05.008 Ghafoor, 2019, Multimodality imaging of prostate cancer, J Nucl Med, 60, 1350, 10.2967/jnumed.119.228320 Parker, 2020, Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 31, 1119, 10.1016/j.annonc.2020.06.011 Santos, 2022, Prostate cancer imaging: What we already know and what is on the horizon, Radiographics, 42, E123, 10.1148/rg.210134 Nörenberg, 2017, [MRI of the prostate], Urologe A, 56, 665, 10.1007/s00120-017-0378-4 Turkbey, 2019, Prostate imaging reporting and data system Version 2.1: 2019 update of prostate imaging reporting and data system version 2, Eur Urol, 76, 340, 10.1016/j.eururo.2019.02.033 Giganti, 2019, The evolution of MRI of the prostate: The past, the present, and the future, AJR Am J Roentgenol, 213, 384, 10.2214/AJR.18.20796 Bjurlin, 2020, Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer, J Urol, 203, 706, 10.1097/JU.0000000000000617 Rawla, 2019, Epidemiology of prostate cancer, World J Oncol, 10, 63, 10.14740/wjon1191 Gandaglia, 2021, Epidemiology and prevention of prostate cancer, Eur Urol Oncol, 4, 877, 10.1016/j.euo.2021.09.006 Rouvière, 2019, Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study, Lancet Oncol, 20, 100, 10.1016/S1470-2045(18)30569-2 O'Connor, 2021, Role of multiparametric prostate MRI in the management of prostate cancer, World J Urol, 39, 651, 10.1007/s00345-020-03310-z Herrmann, 2022, [Multiparametric MRI of the prostate], Urologe A, 61, 428, 10.1007/s00120-022-01806-7 Vargas, 2011, Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness, Radiology, 259, 775, 10.1148/radiol.11102066 Wu, 2017, Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer, Diagn Interv Imaging, 98, 63, 10.1016/j.diii.2016.08.009 Anwar, 2014, Assessment of apparent diffusion coefficient values as predictor of aggressiveness in peripheral zone prostate cancer: comparison with Gleason score, ISRN Radiol, 2014, 10.1155/2014/263417 Franiel, 2021, mpMRI of the Prostate (MR-Prostatography): Updated recommendations of the DRG and BDR on patient preparation and scanning protocol, Rofo, 193, 763 Tsai, 2015, A practical guide to MR imaging safety: what radiologists need to know, Radiographics, 35, 1722, 10.1148/rg.2015150108 Obmann, 2018, Diagnostic accuracy of a rapid biparametric MRI protocol for detection of histologically proven prostate cancer, Urology, 122, 133, 10.1016/j.urology.2018.08.032 Kuhl, 2017, Abbreviated biparametric Prostate MR imaging in men with elevated prostate-specific antigen, Radiology, 285, 493, 10.1148/radiol.2017170129 Woo, 2018, Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: A systematic review and meta-analysis, Am J Roentgenol, 211, W226, 10.2214/AJR.18.19880 Niu, 2018, Diagnostic performance of biparametric MRI for Detection of prostate cancer: A systematic review and meta-analysis, AJR Am J Roentgenol, 211, 369, 10.2214/AJR.17.18946 Kang, 2019, Abbreviated biparametric versus standard multiparametric MRI for diagnosis of prostate cancer: A systematic review and meta-analysis, AJR Am J Roentgenol, 212, 357, 10.2214/AJR.18.20103 Schoots, 2021, PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: Narrative review, AJR Am J Roentgenol, 216, 3, 10.2214/AJR.20.24268 Scialpi, 2020, Round table: arguments in supporting abbreviated or biparametric MRI of the prostate protocol, Abdom Radiol (NY), 45, 3974, 10.1007/s00261-020-02510-w Belue MJ, Yilmaz EC, Daryanani A, Turkbey B. Current status of biparametric MRI in prostate cancer diagnosis: literature analysis. Life (Basel). 2022;12. doi:10.3390/life12060804. Boesen, 2018, Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) study, JAMA Network Open, 1, 10.1001/jamanetworkopen.2018.0219 Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study, Lancet (London, England), 389, 815, 10.1016/S0140-6736(16)32401-1 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Stempel, 2020, MRI in the management of prostate cancer, Semin Ultrasound, CT, MR, 41, 366, 10.1053/j.sult.2020.04.003 Sebesta, 2017, The surgical management of prostate cancer, Semin Oncol, 44, 347, 10.1053/j.seminoncol.2018.01.003 Schlemmer, 2017, Multiparametrische MR-Bildgebung beim Prostatakarzinom, Radiologie up2date, 17, 43, 10.1055/s-0042-122604 Gupta, 2016, Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer, Abdom Radiol (NY), 41, 831, 10.1007/s00261-015-0579-5 Dickinson, 2011, Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting, Eur Urol, 59, 477, 10.1016/j.eururo.2010.12.009 Caglic, 2019, Multiparametric MRI - local staging of prostate cancer and beyond, Radiol Oncol, 53, 159, 10.2478/raon-2019-0021 Gatti, 2022, mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging, Eur Radiol, 32, 4942, 10.1007/s00330-022-08595-9 Ucar, 2022, Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study, Prostate, 82, 1462, 10.1002/pros.24420 Zhang, 2021, (68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study, Eur J Nucl Med Mole Imaging, 48, 483, 10.1007/s00259-020-04863-2 Seyfried, 2021, Diagnostic yield of incremental biopsy cores and second lesion sampling for in-gantry MRI-guided prostate biopsy, AJR Am J Roentgenol, 217, 908, 10.2214/AJR.20.24918 Bohn, 2021, PSMA-Ligand uptake in disseminated epidermoid cysts in a PSMA PET/CT of a patient with recurrent prostate cancer, Clin Nucl Med, 46, e598, 10.1097/RLU.0000000000003749 Mingels, 2021, The influence of colour scale in lesion detection and patient-based sensitivity in [68Ga]Ga-PSMA-PET/CT, Nucl Med Commun, 42, 495, 10.1097/MNM.0000000000001364 Alberts, 2020, The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia, Eur J Nucl Med Mole Imaging, 47, 642, 10.1007/s00259-019-04552-9 Rowe, 2018, PSMA-RADS Version 1.0: A step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies, Eur Urol, 73, 485, 10.1016/j.eururo.2017.10.027 Shetty, 2018, Pitfalls in gallium-68 PSMA PET/CT interpretation: A pictorial review, Tomography, 4, 182, 10.18383/j.tom.2018.00021 Evangelista, 2021, PET/MRI in prostate cancer: A systematic review and meta-analysis, Eur J Nucl Med Mole Imaging, 48, 859, 10.1007/s00259-020-05025-0 Murthy, 2021, The Role of PSMA PET/CT and PET/MRI in the initial staging of prostate cancer, Eur Urol Focus, 7, 258, 10.1016/j.euf.2021.01.016 Mayerhoefer, 2020, PET/MRI versus PET/CT in oncology: A prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations, Eur J Nucl Med Mole Imaging, 47, 51, 10.1007/s00259-019-04452-y Yablon, 2004, Complications of prostate cancer treatment: Spectrum of imaging findings, Radiographics, 24, S181, 10.1148/rg.24si045502 Bedir, 2019, Diagnosis and conservative management of ureteral orifice injury during robotic prostatectomy for a large prostate with a prominent median lobe, J Endourol Case Rep, 5, 39, 10.1089/cren.2018.0109 Rahnama'i, 2021, Current management of post-radical prostatectomy urinary incontinence, Front Surg, 8, 10.3389/fsurg.2021.647656 Saleh, 2015, Management of erectile dysfunction post-radical prostatectomy, Res Rep Urol, 7, 19 Mohsen, 2022, Role of MRI, ultrasound, and computed tomography in the management of prostate cancer, PET Clin, 17, 565, 10.1016/j.cpet.2022.07.002 Ross, 2012, Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?, Am J Surg Pathol, 36, 1346, 10.1097/PAS.0b013e3182556dcd Meijer, 2022, The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer, BJU Int Hövels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022 Torabi, 2004, Current concepts in lymph node imaging, J Nucl Med, 45, 1509 von Below, 2016, Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer, Clin Radiol, 71, 328, 10.1016/j.crad.2015.12.001 Thoeny, 2017, Functional and targeted lymph node imaging in prostate cancer: Current status and future challenges, Radiology, 285, 728, 10.1148/radiol.2017161517 Evangelista, 2013, Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis, Eur Urol, 63, 1040, 10.1016/j.eururo.2012.09.039 Selnæs, 2018, (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients, Eur Radiol, 28, 3151, 10.1007/s00330-017-5213-1 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, The Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Giesel, 2017, F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients, Eur J Nucl Med Mole Imaging, 44, 678, 10.1007/s00259-016-3573-4 Pienta, 2021, A Phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY), J Urol, 206, 52, 10.1097/JU.0000000000001698 Padhani, 2017, Rationale for modernising imaging in advanced prostate cancer, Eur Urol Focus, 3, 223, 10.1016/j.euf.2016.06.018 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Larbi, 2016, Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease, Prostate, 76, 1024, 10.1002/pros.23196 Nakanishi, 2022, Whole-body MRI: detecting bone metastases from prostate cancer, Jpn J Radiol, 40, 229, 10.1007/s11604-021-01205-6 Padhani, 2017, METastasis reporting and data system for prostate cancer: Practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer, Eur Urol, 71, 81, 10.1016/j.eururo.2016.05.033 Barentsz, 2017, Assessing metastatic disease in advanced prostate cancer: It's time to change imaging, Eur Urol, 71, 93, 10.1016/j.eururo.2016.08.045 Donohoe, 2017, Appropriate use criteria for bone scintigraphy in prostate and breast cancer: Summary and excerpts, J Nucl Med, 58, 14n Fleury, 2018, Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer, Oncotarget, 9, 31744, 10.18632/oncotarget.25860 Bénard, 2022, Intra-individual comparison of (18)F-sodium fluoride PET-CT and (99m)Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial, Lancet Oncol, 23, 1499, 10.1016/S1470-2045(22)00642-8 Armstrong, 2018, Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: A secondary analysis of a randomized clinical trial, JAMA Oncol, 4, 944, 10.1001/jamaoncol.2018.1093 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet (London, England), 395, 1208, 10.1016/S0140-6736(20)30314-7 Pyka, 2016, Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer, Eur J Nucl Med Mole Imaging, 43, 2114, 10.1007/s00259-016-3435-0 Fendler, 2023, PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0, Eur J Nucl Med Mole Imaging, 50, 1466, 10.1007/s00259-022-06089-w Anttinen, 2021, Eur Urol Oncol, 4, 635, 10.1016/j.euo.2020.06.012 Grünig, 2021, Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging, Eur J Nucl Med Mole Imaging, 48, 4483, 10.1007/s00259-021-05424-x Vollnberg, 2022, Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies, Eur J Nucl Med Mole Imaging, 49, 3910, 10.1007/s00259-022-05745-5 Rao, 2019, Oligometastatic prostate cancer: A shrinking subset or an opportunity for cure?, Am Soc Clin Oncol Educ Book, 39, 309, 10.1200/EDBK_239041 Hicks, 2017, Seduction by sensitivity: Reality, illusion, or delusion? the challenge of assessing outcomes after PSMA imaging selection of patients for treatment, J Nucl Med, 58, 1969, 10.2967/jnumed.117.198812 Pisansky, 2019, Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019, J Urol, 202, 533, 10.1097/JU.0000000000000295 Lowrance, 2021, Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART I, J Urol, 205, 14, 10.1097/JU.0000000000001375 Briganti, 2014, Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy, Eur Urol, 66, 479, 10.1016/j.eururo.2013.11.045 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 Update: Treatment of relapsing and metastatic prostate cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046 Pucar, 2008, The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery, Curr Opin Urol, 18, 87, 10.1097/MOU.0b013e3282f13ac3 Panebianco, 2021, Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy, Eur Urol Oncol, 4, 868, 10.1016/j.euo.2021.01.003 Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European journal of nuclear medicine and molecular imaging. 2015;42:197-209. doi:10.1007/s00259-014-2949-6. Afshar-Oromieh A, Vollnberg B, Alberts I, et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. European journal of nuclear medicine and molecular imaging. 2019;46:2289-97. doi:10.1007/s00259-019-04438-w. Alberts, 2021, Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT – effects on lesion visibility and radiotracer uptake, J Nucl Med, 62, 1252, 10.2967/jnumed.120.257741 Afshar-Oromieh, 2021, Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients, Eur J Nucl Med Mole Imaging, 48, 2925, 10.1007/s00259-021-05189-3 Mingels, 2022, Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer, Eur J Nucl Med Mole Imaging, 49, 2436, 10.1007/s00259-022-05693-0 Alberts, 2022, Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: A Markov chain decision analysis, Eur J Nucl Med Mole Imaging, 49, 4252, 10.1007/s00259-021-05620-9 Alberts, 2021, Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences, Eur J Nucl Med Mole Imaging, 48, 4456, 10.1007/s00259-021-05438-5 Alberts, 2020, Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: A matched-pair comparison, Eur J Nucl Med Mole Imaging, 47, 614, 10.1007/s00259-019-04630-y Mingels, 2023, Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT, Ann Nucl Med, 37, 310, 10.1007/s12149-023-01827-y Alberts, 2021, Clinical performance of long axial field of view PET/CT: A head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT, Eur J Nucl Med Mole Imaging, 48, 2395, 10.1007/s00259-021-05282-7 Alberts, 2021, Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [(18)F]-FDG PET/CT, Ann Nucl Med, 35, 485, 10.1007/s12149-021-01588-6 Sachpekidis, 2022, Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma, Eur J Nucl Med Mole Imaging, 50, 1158, 10.1007/s00259-022-06070-7 Triumbari, 2023, Long axial field-of-view PET/CT could answer unmet needs in gynecological cancers, Cancers, 15, 2407, 10.3390/cancers15092407 Daryanani, 2022, Recent advancements in CT and MR imaging of prostate cancer, Semin Nucl Med, 52, 365, 10.1053/j.semnuclmed.2021.11.013 Gordon, 2020, Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer, Clin Exp Metastasis, 37, 305, 10.1007/s10585-020-10027-1 Alberts, 2022, Afshar-Oromieh A. A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale, PLoS One, 17, 10.1371/journal.pone.0270269 Pattison, 2022, Prospective intra-individual blinded comparison of [(18)F]PSMA-1007 and [(68) Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer, Eur J Nucl Med Mol Imaging, 49, 763, 10.1007/s00259-021-05520-y Alberts, 2021, Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis, Eur J Nucl Med Mol Imaging, 48, 2978, 10.1007/s00259-021-05210-9 Alberts, 2020, Afshar-Oromieh A. PSMA-negative prostate cancer and the continued value of choline-PET/CT, Nuklearmedizin, 59, 33, 10.1055/a-1044-1855 Iravani, 2021, Molecular imaging of neuroendocrine differentiation of prostate cancer: A case series, Clin Genitourin Cancer, 19, e200, 10.1016/j.clgc.2021.01.008 Fech, 2019, PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography, Nuklearmedizin Cysouw, 2019, Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer, EJNMMI Res, 9, 70, 10.1186/s13550-019-0531-8 Fox, 2018, Positron Emission Tomography/Computed Tomography–based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer, JAMA Oncol, 4, 217, 10.1001/jamaoncol.2017.3588 Alberts, 2022, Afshar-Oromieh A. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy, European J Nucl Med Mole Imaging Cheng, 2012, Staging of prostate cancer, Histopathology, 60, 87, 10.1111/j.1365-2559.2011.04025.x